Clinical Response and Safety of Alternating Daily Dosage of Crizotinib due to Side Effects in Advanced NSCLC patient harboring ROS1-rearrangement: A Case Report. J Respirol Indones [Internet]. 2023 Apr. 16 [cited 2025 Aug. 14];43(2):111-5. Available from: http://jurnalrespirologi.org/index.php/jri/article/view/201